Analysts expect that Henry Schein, Inc. (NASDAQ:HSIC) will post earnings per share of $1.73 for the current fiscal quarter, Zacks reports. Nine analysts have provided estimates for Henry Schein’s earnings, with the highest EPS estimate coming in at $1.75 and the lowest estimate coming in at $1.70. Henry Schein reported earnings of $1.64 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 5.5%. The firm is scheduled to issue its next earnings results on Thursday, August 3rd.

According to Zacks, analysts expect that Henry Schein will report full year earnings of $7.28 per share for the current year, with EPS estimates ranging from $7.23 to $7.30. For the next fiscal year, analysts forecast that the firm will report earnings of $8.04 per share, with EPS estimates ranging from $7.94 to $8.30. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Henry Schein.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Tuesday, May 9th. The company reported $1.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.65 by $0.11. The firm had revenue of $2.92 billion during the quarter, compared to analysts’ expectations of $2.83 billion. Henry Schein had a return on equity of 20.23% and a net margin of 5.07%. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.41 EPS.

A number of research firms recently commented on HSIC. Zacks Investment Research raised Henry Schein from a “hold” rating to a “buy” rating and set a $206.00 price objective on the stock in a research note on Friday. Barrington Research lifted their price objective on Henry Schein from $196.00 to $198.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 10th. Leerink Swann set a $183.00 price objective on Henry Schein and gave the stock a “hold” rating in a research note on Wednesday, February 22nd. Deutsche Bank AG began coverage on Henry Schein in a research note on Wednesday, March 15th. They issued a “hold” rating and a $174.00 price objective on the stock. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $165.00 price objective on shares of Henry Schein in a research note on Tuesday, February 28th. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $184.08.

In related news, SVP Lorelei Mcglynn sold 9,300 shares of Henry Schein stock in a transaction that occurred on Thursday, March 23rd. The stock was sold at an average price of $171.76, for a total transaction of $1,597,368.00. Following the transaction, the senior vice president now owns 33,048 shares of the company’s stock, valued at $5,676,324.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Gerald A. Benjamin sold 12,578 shares of Henry Schein stock in a transaction that occurred on Thursday, May 11th. The shares were sold at an average price of $175.10, for a total value of $2,202,407.80. Following the transaction, the executive vice president now directly owns 44,061 shares in the company, valued at approximately $7,715,081.10. The disclosure for this sale can be found here. Insiders own 1.27% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Girard Partners LTD. boosted its position in shares of Henry Schein by 0.3% in the first quarter. Girard Partners LTD. now owns 3,115 shares of the company’s stock valued at $529,000 after buying an additional 10 shares during the last quarter. Cleararc Capital Inc. boosted its position in Henry Schein by 0.6% in the first quarter. Cleararc Capital Inc. now owns 1,950 shares of the company’s stock valued at $331,000 after buying an additional 11 shares in the last quarter. Penserra Capital Management LLC boosted its position in Henry Schein by 1.0% in the first quarter. Penserra Capital Management LLC now owns 1,518 shares of the company’s stock valued at $258,000 after buying an additional 15 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in Henry Schein by 0.8% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 2,576 shares of the company’s stock valued at $391,000 after buying an additional 21 shares in the last quarter. Finally, Wetherby Asset Management Inc. boosted its position in Henry Schein by 0.7% in the first quarter. Wetherby Asset Management Inc. now owns 3,147 shares of the company’s stock valued at $535,000 after buying an additional 21 shares in the last quarter. 90.74% of the stock is currently owned by institutional investors.

Shares of Henry Schein (NASDAQ HSIC) traded up 1.03% during mid-day trading on Monday, reaching $184.62. The company’s stock had a trading volume of 117,905 shares. The company has a 50-day moving average of $180.32 and a 200-day moving average of $167.54. The firm has a market cap of $14.65 billion, a PE ratio of 28.06 and a beta of 1.10. Henry Schein has a 12 month low of $146.23 and a 12 month high of $186.99.

COPYRIGHT VIOLATION NOTICE: “Henry Schein, Inc. (HSIC) Expected to Post Earnings of $1.73 Per Share” was reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another publication, it was illegally copied and republished in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/06/19/henry-schein-inc-hsic-expected-to-post-earnings-of-1-73-per-share.html.

About Henry Schein

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Get a free copy of the Zacks research report on Henry Schein (HSIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.